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Abstract: Objective: To record which interventions produce the greatest variations in body
composition in patients ≤19 years old with metabolic syndrome (MS). Method: search dates between
2005 and 2017 in peer reviewed journals, following the PRISMA method (Preferred Reporting Items
for Systematic reviews and Meta-Analyses). The selection criteria were: diagnostic for MS or at
least a criterion for diagnosis; randomized clinical trials, ≤19 years of age; intervention programs
that use diet and/or exercise as a tool (interventions showing an interest in body composition).
Results: 1781 clinical trials were identified under these criteria but only 0.51% were included.
The most frequent characteristics of the selected clinical trials were that they used multidisciplinary
interventions and were carried out in America. The most utilized parameters were BMI (body mass
index) in kg/m2 and BW (body weight) in kg. Conclusions: Most of the clinical trials included had
been diagnosed through at least 2 diagnostic criteria for MS. Multidisciplinary interventions obtained
greater changes in body composition in patients with MS. This change was especially prevalent in the
combinations of dietary interventions and physical exercise. It is proposed to follow the guidelines
proposed for patients who are overweight, obese, or have diabetes type 2, and extrapolate these
strategies as recommendations for future clinical trials designed for patients with MS.
Keywords: metabolic syndrome; children; adolescents; diet; exercise; body composition; weight and fat
1. Introduction
1.1. Definitions
Diabetes (Diabetes mellitus: DM): serious medical condition in which body cannot control the
amount of sugar in your blood.
Insulin resistance: is a pathology in which cells fail to respond normally to the hormone insulin.
Insulin controls the concentrations of glucose in blood and it is produced by the pancreas when glucose
starts to be released into the bloodstream from the digestion of carbohydrates (primarily) in the diet.
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Under normal conditions of insulin reactivity, this insulin response triggers glucose being taken into
body cells, to be used for energy, and inhibits the body from using fat for energy, thereby causing the
concentration of glucose in the blood to decrease. This, glucose concentration stays within the normal
range even when a large amount of carbohydrates is consumed. During insulin resistance, excess
glucose is not sufficiently absorbed by cells even in the presence of insulin, thereby causing an increase
in the level of blood sugar. The insulin resistance syndrome (metabolic syndrome or syndrome X),
and prediabetes are closely related and the show overlapping aspects.
Prediabetes (or “Pre-diabetic state): precursor stage before diabetes mellitus in which blood sugar
is abnormally high. This stage is not a disease itself. Prediabetes is associated with obesity (especially
abdominal or visceral obesity), dyslipidemia with high triglycerides and/or low HDL cholesterol,
and hypertension. Thus, it is considered a metabolic diathesis or syndrome. Impaired fasting blood
sugar and impaired glucose tolerance are two forms of prediabetes that are similar in clinical definition
but are physiologically distinct.
Impaired glucose intolerance (IGT): pre-diabetic state of hyperglycemia that is associated with
insulin resistance and increased risk of cardiovascular pathology. IGT may precede type 2 diabetes
mellitus by many years
Isolated impaired fasting glucose (IFG): pre-diabetic state in which the concentrations of sugar in
blood during fasting are consistently above the normal range, but below the diagnostic cut-off for a
formal diagnosis of diabetes mellitus. Together with impaired glucose tolerance, it is a sign of insulin
resistance. In this manner, it is also one of the conditions associated with Metabolic Syndrome.
1.2. Noncommunicable Diseases (NCDs)
Cardiovascular pathologies, cancers, chronic respiratory illnesses and diabetes are the primary
causes of death around the world. More than 36 million people die annually from NCDs, which
account for 63% of all deaths worldwide. These deaths are caused by poor diet, physical inactivity and
the harmful use of alcohol and tobacco [1,2].
To prevent the development of these NCDs, the “Global Action Plan for the Prevention and
Control of NCDs 2013–2020” was put into place by WHO (World Health Organization) and by the
European health policy framework, Health 2020; thus, indicating a forward path for government and
society. Among the voluntary global objectives, the following stand out: the reduction of widespread
insufficient physical activity and the prevention of diabetes and obesity [1,2].
1.3. Metabolic Syndrome (MS): Concept and Prevalence (Tables 1 and 2)
Metabolic syndrome, also known as “Insulin Resistance Syndrome”, can be defined as a series
of physiological, biochemical and metabolic factors that increase the risk for cardiovascular disease
and type 2 diabetes (T2DM). These factors include insulin resistance, T2DM or glucose intolerance,
hypertension and central obesity [3–12].
The concept of MS in the pediatric population is difficult to define due to the physiological
changes throughout their growth and development, racial differences, and the lack of cardiovascular
events [11,13]. The amount of clinical trials available on this age group is scarce, and therefore, a universal
definition for children and adolescents does not exist thus far [11,13–15]. Since 2001, adaptations of the
standardized adult MS definitions have been applied to the juvenile clinical trials [11,13,15,16].
These adaptations lead to excessive variety in diagnosis of MS. For example, the prevalence of MS
in adolescents in the United States has been greater than 10% (2000–2010) [17]. However, depending
on which diagnostic criteria is used, the prevalence can vary between 0.9, 3.8, 4.1, 10.5 and 11.4%. This
wide variation can be directly attributed to the inconsistent terms and definition of MS in children and
adolescents (Tables 1 and 2) [18,19].
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The diagnosis of obesity has evolved over time. The current definition of obesity based on weight
and height cannot accurately identify all causes obesity-related risk of CVD (cardiovascular disease).
People with a normal BMI (body mass index) and high content of BF (body fat) are at greater risk of
metabolic disturbance, systemic inflammation and mortality. Thus, the metabolic alteration observed
in individuals with normal weight metabolic obese can be only due to the increase of body adiposity
not detected by the BMI [20].
1.4. Strategies for Intervention in Overweight, Obesity and T2DM
Thus far, specific guidelines for the treatments of MS have not been detailed. Therefore, evaluation
and intervention guidelines on overweight, obesity and T2DM are presented (Tables 3 and 4).
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Table 1. Diagnosis of metabolic syndrome in children and adolescents.
AHA Criteria [21] IDF Criteria WHO Criteria NCEP ATP III Criteria
Necessary components for the
MS diagnosis
3 of the 5 must be
present Central obesity and 2 of 4 other components must be present [21]
At least 3 or
hyperinsulinemia and at
least 2 must be present [22]
At least 3 must be present [23]
Age (years) 12–19 6–9 [21] 10–15 [21]10–16 [23]
>15 [21]
≥16 [24] ND ND
Essential criteria ND ND ND ND Insulin resistance [23] None [23]
Waist circumference
WC ≥ 90th percentile
for age, sex and
race/ethnicity
WC ≥ 90th
percentile for age
(MS as entity is not
diagnosed) [21]
WC ≥ 90th percentile
[23] or adult cut-off if
lower [21]
WC ≥ 90 cm in boys and
≥80 cm in girls [24]
WC ≥ 94 cm in boys and
≥80 cm in girls [21]
Waist-to-hip ratio > 0.9 in
boys and >0.85 in girls [23]
BMI ≥ 75/85/95th
percentile by age, sex [22]
WC ≥102 cm in boys and
≥88 cm in girls [23]
WC > 90th percentile or BMI
≥ 97th percentile [22]
WC > 75th percentile for age
and sex [24]
BMI ND ND ND ND >30 kg/m2 [23] ND
Blood pressure ≥90th percentile forage, sex, and height ND
SBP ≥ 130 mmHg [23]
SBP ≥ 130 mmHg or
DBP ≥ 85 mmHg [24]
SBP ≥ 130 mmHg or DBP
≥85 mmHg [24] or treatment
of previously diagnosed
hypertension [21]
SBP ≥ 140 mmHg [23]
SBP ≥ 130 mmHg [23]
SBP > 90th percentile for age
and sex [24]
Dyslipidemia
Triglyceride ≥1.23 mmol/L(≥110 mg/dL) ND
≥1.7 mmol/L
(≥150 mg/dL) [23]
≥1.7 mmol/L (≥150 mg/dL)
[24] or specific treatment for
high triglycerides [21]
≥1.7 mmol/L
(≥150 mg/dL) [23]
≥1.7 mmol/L (≥150 mg/dL)
[23] ≥100 mg/dL [24]
HDL-C ≤10th percentile forrace and sex [21] ND
<1.03 mmol/L
(<40 mg/dL) [23]
<1.03 mmol/L (<40 mg/dL)
in boys and <1.29 mmol/L
(<50 mg/dL) in girls [24] or
specific treatment for low
HDL-C [21]
<0.91 mmol/L in boys
<1.0 mmol/L in girls [23]
<1.0 mmol/L [23]
500 mg/dL, except boys from
15 to 18 years, whose cutoff
point was <45 mg/dL [24]
Glucose
Fasting glucose
≥5.6 mmol/L
(≥100 mg/dL) [21]
ND
Fasting glucose
≥5.6 mmol/L
(≥100 mg/dL) [23]
Fasting glucose ≥5.6 mmol/L
(≥100 mg/dL) [24] or known
T2DM [21]
Insulin resistance or
diabetes [23]
Fasting glucose ≥
6.1 mmol/L (≥110 mg/dL)
or ≥80/90th percentile by
age, sex or diabetes [22]
Fasting glucose ≥6.1 mmol/L
(≥110 mg/dL) [23]
Fasting glucose ≥5.6 or
6.1 mmol/L (≥100 or
110 mg/dL) or 2 h glucose
≥140 mg/dL [22]
Insulin ND ND ND ND Insulin resistance [23] ND
AHA: American Heart Association; BMI: body mass index; cm: centimeters; DBP: diastolic blood pressure; HDL-C: high-density lipoprotein cholesterol (lipoproteins that carry cholesterol
from the tissues of the body to the liver); IDF: International Diabetes Federation; MS: metabolic syndrome; NCEP ATP III: National Cholesterol Education Program’s Adult Treatment
Panel; ND: not declared; SBP: systolic blood pressure; T2DM: type 2 diabetes mellitus (type of glycerol that belongs to the family of lipids, in mammals it is transported throughout the
body while supplying energy or is stored as fat, for long periods; WC: waist circumference; WHO: World Health Organization.
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Table 2. Diagnostic criteria for prediabetes, impaired glucose tolerance and type 2 diabetes mellitus in children and adolescents.
WHO Criteria ADA Criteria
Prediabetes [25] Glucose
Fasting plasma glucose 110–125 mg/dL(6.1–6.9 mmol/L)
100–125 mg/dL
(5.6–6.9 mmol/L)
Random Plasma Glucose ND Not applicable
2-h plasma glucose (OGTT) 140–200 mg/dL(7.8–11.0 mmol/L)
140–200 mg/dL
(7.8–11.0 mmol/L)
Hemoglobin A1c ND 5.7–6.4%
Impaired glucose tolerance [26] Glucose 2-h plasma glucose (OGTT) ND 140–199 mg/dL(7.8–11.0 mmol/L)
Type 2 Diabetes Mellitus [25,26] Glucose
Fasting plasma glucose ND ≥126 mg/dL(7.0 mmol/L)
Random Plasma Glucose ND ≥200 mg/dL(11.1 mmol/L)
2-h plasma glucose (OGTT) ND ≥200 mg/dL(11.1 mmol/L)
Hemoglobin A1c ND ≥6.5%
ADA: American Diabetes Association; Fasting plasma glucose: fasting for at least 8 h with no calorie intake; OGTT (2-h plasma glucose): OGTT using a load of glucose 1.75 g/kg of body
weight, with a maximum of 75 g; Random plasma glucose: In patients with hyperglycemic crises or classic symptoms of hyperglycemia (e.g., polyuria, polydipsia); diabetes: In the absence
of unequivocal hyperglycemia, diagnosis is confirmed if two different tests are above threshold or a single test is above threshold twice; A1c: glycosylated hemoglobin; OGTT: Oral
Glucose Tolerance Test; ND: Not Declared; WHO: World Health Organization.
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Table 3. Guidelines and consensus on the treatment of overweight and obesity: children and adolescents *.
Author Recommendations in Dietary Intervention and Exercise
Overweight and
obesity
AND [27] Intervention: divided into three levels: primary, secondary and tertiary preventionEvidence: 2009 Academy of Nutrition and Dietetics (Figure 1) [28]
ICSI [29]
Intervention: during the day, diet and physical activity. It identifies 4 levels of intervention in patients with BMI ≥ 85th
percentile: prevention, structures weight management, integral multidisciplinary intervention, tertiary intervention
Dietary intervention: the consumption of a diet with very low energy density
BW: age, 2–11 years = 1 lb or 0.45 kg mo−1; age, 12–18 years = 2 lb or 0.91 kg wk−1
Evidence: [29]
T2DM [30]
Dietary intervention:
1. Interventions to reduce pediatric obesity should be multicomponent and include diet, physical activity, nutritional
consulting and require participation of the parents or guardians.
2. A nutritional prescription should be formulated as part of the dietary intervention in a multi component pediatric
weight control program.
3. The dietary factors that can be associated with the greatest risk for obesity are increasing the total amount of fats in
diet as well as increasing the intake of beverages.
4. The dietary factors that can be associated with the least risk for obesity is the increase of fruits and vegetables.
5. The familiar dietary behaviors that are associated with the greatest risk for pediatric obesity are the parental
restriction of healthy foods, the consumption of food outside the house (e.g., fast food), the large portion sizes of
meals and the skipping of breakfast.
Evidence: does not use the system of degrees of evidence
* Extensive information is given in Table 4; AND: Academy of Nutrition and Dietetics; ICSI: Health Care Guideline; VLCD: very low energy density diets; day (d); kilograms (Kg); minutes
(min); month (mo); week (wk); pounds (lb).
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Table 4. Intervention strategies for the reduction of body composition in overweight, obesity and T2DM: children and adolescents.
Dietary Intervention
Energy
restriction
Overweight and obesity 1000 a 2000 Kcal day−1 [27]
T2DM ≥1200 Kcal day−1 in ages between 6 and 12 years old [30]
VLCD
Overweight and obesity ≤1.000 Kcal day−1 ó 600 a 800 Kcal day−1 (PSMF) [27]
T2DM ≥900 Kcal day−1 in ages between 6 and 12 years old [30]
Macronutrients and diets
Different quantities of macronutrients (carbohydrates, proteins and fats) and different types of diets; PSMF (10–20 weeks), proteins
(1.5 to 2.0 g kg−1 to reach the optimum body weight), carbohydrates (20–25 g day−1), water and other liquids without calories (2 L day−1),
daily multivitamin supplements, balanced diet (for 10 weeks) [27]
Physical exercise
Overweight and obesity
≤2 years old should not watch television, supervised free play is encouraged; 4 to 6 years old, up to 120 min of moderate to rigorous physical
activity (MVPA) each day, 60 min in structured activity and 60 min of free play; ≥10 years old, at least ≥60 min day−1 of physical activity
which should consist primarily of MVPA. In adolescents, promote and incorporate more complex and personalized activities [29]
T2DM
Children and adolescents with T2DM should practice moderate to vigorous physical activity for at least 60 min day−1 a day [27,31]
Limited television time, to less than 2 h per day [27]
Evidence grade D: expert opinions and evidence from metabolic syndrome and obesity studies. Prevalence of benefits over the harms.
T1DM: Diabetes mellitus type 1; PSMF: high protein diet.
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Guides and/or algorithms for the management of the treatment of overweight, obesity and
diabetes are technical reports supported by evidence. They contain an outline of interventions,
indicating what must be done on these pathologies. Tables 3 and 4 summarize some guidelines,
however, there are other guides not mentioned in this work [32–37]. Most of these guides are revised
to evaluate the degree of evidence for each recommendation (Table 3). Thus, these guides show a
consensus in the evidence regarding dietary techniques and physical exercise (Table 3). However,
there are differences between the consensus established between these guides in terms of energy
restriction and the recommendations related to the percentage of intake of macronutrients (Table 4).
The consensus was obtained from clinical trials where the authors observed a decrease of BMI and/or
body weight. Probably, this controversy could disappear if guides and/or algorithms record those
clinical trials that consider the BMI and/or weight along with other anthropometric parameters, such
as body fat and fat-free mass [38–41].
1.5. Changes in Body Composition Andmetabolic Abnormalities
At present the metabolic changes are being considered as a cardiometabolic syndrome, which is
a set of various risk factors such as abdominal obesity, hypertension or hypertension, dyslipidemia,
and prediabetes [42,43]. In response to this syndrome or metabolic alterations, the need has emerged
to use better tools to monitor the patterns of individual growth, assess body composition in risk and
identify those who are at increased risk of developing metabolic components of the disease. The risk
assessment of this pathology should be evaluated beyond the capacity of the BMI and/or body weight,
hence the need arises for other anthropometric parameters, such as the percentage of body fat, fat-free
mass and/or skeletal muscle mass [40,41].
Current evidence suggests that the intervention of physical exercise in adolescents with
overweight and obesity improves body composition, changes body fat, and therefore could improve
some cardio-metabolic factors [44]. In the lifestyle interventions, the authors of these studies relate the
changes in body weight with the cardio-metabolic results [45]. The most traditional dietary patterns,
including the Mediterranean diet, are associated with better metabolic profiles [46].
1.6. Use of Pharmacology in the Interventions of Changes Body Composition
The advantage of using medication in interventions for the management of weight loss in patients
aged 2 to 18 years is not yet clear [32,47]. In relation to the use of drugs in children and adolescents
with prediabetes in 2017, clinical guidelines from the Endocrine Society recommend that pediatricians
abstain from prescribing pharmacotherapy, including metformin [48]. However, there are other
bibliographic sources that recommend its use [30,49]. The American Diabetes Association recognizes
insulin and metformin as treatment for T2DM [50].
1.7. Theoretical Framework and Purpose of the Review
The interest and novelty of this systematic review are justified by the following premises:
1. Due to the prevalence observed in children and adolescents with MS [17–19].
2. The search for which dietary intervention and physical exercise obtains greater changes in body
composition in children and adolescents with MS, as described by the overweight, obesity and
T2DM guidelines [27,29,30].
3. The relationship between the changes in body composition and cardio-metabolic factors [44,45].
4. Adhering to the WHO Global Action Plan in the reduction [1,2], which is focused on the factors
related to the diagnosis of MS [3,4].
The principal objective is to record which interventions produce the greatest variations in body
composition in patients ≤19 years old with MS.
The secondary objectives are: (a) to identify which interventions, produce the greatest changes
in body composition in patients ≤19 years of age with MS, either exclusive or multidisciplinary;
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(b) to indicate which anthropometric parameters and units of measurement were the most used to
record changes in body composition in patients ≤19 years old with MS.
2. Method
2.1. Selection Criteria of the Clinical Trials and Search Strategy
The selection criteria were: randomized clinical trials in humans; patients ≤19 years old [51]
that had been diagnosed with MS and otherwise, should have been diagnosed using at least two
diagnostic criteria (T2DM, high blood pressure, insulin resistance, hyperinsulinemia, hyperinsulinism,
hyperglycemia, dislipemia, glucose intolerance and/or prediabetes) (Tables 1 and 2); intervention
programs including diet, physical exercise and/or modifications in the style of life as treatment as well
as the magnitude of changes in body composition; clinical trials published between 2005 and 2017
in scientific journals and in Spanish and English (Table 6). The exclusion criteria are detailed in the
flowchart, Figure 1.
This observational investigation was based upon a systematic review following the recommended
guidelines of PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses,
Table S1) [52–54] and it used the information retrieval system “the Boolean Model” [55]. All data used
were collected from the following databases: PubMed, EBSCOhost, ProQuest and Web of Science in
articles of original clinical trials. The key words were: metabolic syndrome, children, teens, pediatrics,
diet and exercise; the database “MeSH” (Medical Subject Headings) (Table 5 and Figure 1).
Using EBSCOhost, all of the databases that included the following options were selected:
“AB Summary” and “academic publications” in types of publications; in PubMed an advanced search
was used and the following options were selected: “Title/Abstract” and type of article was “Clinical
Trial”; in ProQuest an advanced search was used and the following options were selected: “scientific
journals” in type of source, “Primary article” in type of document and “Abstract”; in Web of Science a
basic search was used and the following options were selected: “Clinical Trial” in types of documents
and “theme”.
The primary research question was: which are the clinical trials reporting the greatest variations
in body composition, in patients <19 years old with MS?
2.2. Data Extraction, Synthesis of Results and Risk of Information Loss
Six tables and 3 figures were designed to execute this systematic review. Tables 1–4 identify the
most relevant background information for the design of the theoretical framework. The flowchart
displays the selection process of the clinical trials included (Figure 1).
Table 5 reflects which strategies and databases were utilized. Table 6 records the most relevant
details about the clinical trials included and was ordered from the simplest intervention techniques
(exclusive) to the most difficult (multidisciplinary). The searches were made independently (one for
each of the authors). Therefore, there were five versions of Table 6, all of them including as much
information as possible from the trials included. The rest of the tables were performed jointly.
As for the risk of information loss, only one clinical trial was found where the authors diagnosed
MS (Table 6) [56]. Heterogeneous designs were identified in the selected clinical trials. The variations
found were: the use of great diversity in the MS diagnostic criteria (Table 1), signs and/or pathologies
prior to having MS (Table 2); disparity in the number of patients and their age; temporal duration;
diversity in the intervention strategies used; diversity in the anthropometric parameters and units
with which the changes of body composition are expressed (Table 6).
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Table 5. Search strategies of identified and included clinical trials, dates: 2005–2017.
Search strategy EBSCOhostIdentified/Included
ProQuest
Identified/Included
PubMed
Identified/Included
Web of Science
Identified/Included
“metabolic syndrome” AND “children” OR “teens” OR “pediatrics” AND “diet” OR “dietary treatment”
OR “feeding” AND “nutrition” OR “nutritional counseling” OR “lifestyle” 12/0 25/0 3/0 32/1
“metabolic syndrome” AND “children” OR “teens” OR “pediatrics” AND “exercise” OR “physical
activity” OR “sport” OR “weightlifting” 54/0 90/0 13/0 44/2
“metabolic syndrome” AND “children” OR “teens” OR “pediatrics” AND “weight loss” OR “weight
reduction” OR “fat loss” OR “fat reduction” 12/0 27/0 8/0 277/3
“type II diabetes” OR “insulin resistance” OR “hyperinsulinism” OR “hyperinsulinaemia” OR
“hyperglycemia” OR “dyslipidemia” OR “prediabetes” AND “children” OR “teens” OR “pediatrics” AND
“weight loss” OR “weight reduction” OR “fat loss” OR “fat reduction”
29/1 75/1 25/2 88/7
“type II diabetes” OR “insulin resistance” OR “hyperinsulinism” OR “hyperinsulinaemia” OR
“hyperglycemia” OR “dyslipidemia” OR “prediabetes” AND “children” OR “teens” OR “pediatrics” AND
“diet” OR “dietary treatment” OR “feeding” AND “nutrition” OR “nutritional counseling” OR “lifestyle”
23/0 55/0 13/1 78/2
“type II diabetes” OR “insulin resistance” OR “hyperinsulinism” OR “hyperinsulinaemia” OR
“hyperglycemia” OR “dyslipidemia” OR “prediabetes” AND “children” OR “teens” OR “pediatrics” AND
“exercise” OR “physical activity” OR “sport” OR “weightlifting”
114/0 200/0 65/1 135/6
“metabolic syndrome” AND “hypertension” OR “high blood pressure” AND “children” OR “teens” OR
“pediatrics” AND “weight loss” OR “weight reduction” OR “fat loss” OR “fat reduction” 3/0 6/0 0/0 45/0
“metabolic syndrome” AND “hypertension” OR “high blood pressure” AND “children” OR “teens” OR
“pediatrics” AND “diet” OR “dietary treatment” OR “feeding” AND “nutrition” OR “nutritional
counseling” OR “lifestyle”
4/0 13/0 0/0 40/0
“metabolic syndrome” AND “hypertension” OR “high blood pressure” AND “children” OR “teens” OR
“pediatrics” AND “exercise” OR “physical activity” OR “sport” OR “weightlifting” 11/0 25/0 1/0 136/0
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Table 6. Characteristics of included randomized trials in children and adolescents.
Author [56–64] Sample/DiagnosticCriteria
Duration
(Months)
Intervention and
Comparative
Statistical Analysis of
the Body Composition
BW (kg or
z-Score/%)
BF (kg or %
of BW)
FFM
(kg/)
LM
(kg)
BMI
(kg/m2 or % of 95th
Percentile or z-Score)
WC (cm)
Changes in Body
Composition
Mean± sd or
Mean± (SE) or
Mean (CI, 95%)
Armeno et al.,
2011 [57]
n = 86
IG1: 47
IG2: 39
Girls: 58%
Age: 11–19 years old
Population: South
America (Argentina)
Obesity and Insulin
Resistance, source of
diagnostic criteria:
95th Percentile /NE
4 Dietary intervention
Within groups:
IG1 (low insulin
response diet)
IG2 (conventional diet)
Between groups
YES (kg and
z-score)
NE
NE
NS
YES (kg)
NE
NE
NE
NO NO YES (kg/m2 and
z-score)
NE
NE
NS
YES
NE
NE
p < 0.05
BW:
IG1: 8.9 kg
IG2: −6.4 kg
IG1: −0.53 ± 0.5 (z-score)
IG2: −0.54 ± 0.4 (z-score)
BF:
IG1: −5.12 kg
IG2: NE
BMI:
IG1: −3.9 kg/m2
IG2: −2.9 kg/m2
IG1: −0.35 ± 0.2 (z-score)
IG2: −0.36 ± 0.2 (z-score)
WC:
IG1: −9.1 ± 4.8 cm
IG2: −6.6 ± 4.6 cm
Van der Aa et al.,
2016 [58]
n = 42
IG1: 23
IG2: 19
Girls: 66%
Age: 10–16 years old
Population: Europe
(The Netherlands)
Obesity and Insulin
Resistance, source of
diagnostic criteria:
NE/NE
18 Physical exercise
intervention,
pharmacology
Within groups:
IG1 (metformin)
IG2 (placebo)
Between groups
YES (kg)
NE
NE
NE
YES (kg and
% of BW)
NE
NE
p < 0.05/NS
YES
NE
NE
p < 0.05
NO YES (kg/m2)
NE
NE
p < 0.05
YES
NE
NE
NE
BW (3):
IG1: 1.6 kg (−4.2, 5.9)
IG2: 12 kg (2.7, 17)
BF (3):
IG1: −0.2 kg (−5.2, 2.1)
IG2: 2 kg (1.2, 6.4)
IG1: −3.1% (−4.8, 0.3)
IG2: −0.8% (−3.2, 1.6)
FFM (3):
IG1: 2.0 kg (−0.1, 4)
IG2: 4.5 kg (1.3, 11.6)
BMI (3):
IG1: 0.2 kg/m2 (−2.9, +1.3)
IG2: 1.2 kg/m2 (−0.3, 2.4)
WC (3):
IG1 and IG2 NE (cm)
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Table 6. Cont.
Author [56–64] Sample/DiagnosticCriteria
Duration
(Months)
Intervention and
Comparative
Statistical Analysis of
the Body Composition
BW (kg or
z-Score/%)
BF (kg or %
of BW)
FFM
(kg/)
LM
(kg)
BMI
(kg/m2 or % of 95th
Percentile or z-Score)
WC (cm)
Changes in Body
Composition
Mean± sd or
Mean± (SE) or
Mean (CI, 95%)
Garnett et al., 2013
[59]
n = 111
IG1: 55
IG2: 56
Girls: 61%
Age: 10–17 years old
Population: Oceania
(Australia)
Overweight and
Obesity/Prediabetes
and/or Insulin
Resistance, source of
diagnostic criteria:
International Obesity
Task Force/ADA/NE
6 Dietary and physical
exercise intervention,
pharmacology
Within groups:
IG1 (high CH diet)
IG2 (low CH diet)
Between groups
YES (kg)
NE
NE
NE
NO NO NO YES (% of 95th
percentile)
p < 0.05
p < 0.05
NS
NO BW:
Total: −3.7 kg (median)
BMI:
Total NE % 95th percentile
Gómez-Díaz et al.,
2012 [60]
n = 52
IG1: 28
IG2: 24
Girls: 56%
Age: 4–17 years old
Population: North
America (Mexico)
Glucose Intolerance,
source of diagnostic
criteria: ADA
3 Dietary intervention,
physical exercise
education,
pharmacology
Within groups:
IG1 (metformin)
IG2 (placebo)
Between groups
YES (kg)
/YES
p < 0.05
p < 0.05
NS/ p < 0.05
NO NO NO YES (kg/m2)
p < 0.05
p < 0.05
NS
YES
p < 0.05
p < 0.05
NS
BW:
IG1: −2.7 kg
IG1: −5.86%
IG2: −1.6 kg
IG2: −2.75%
BMI:
IG1: −4.3 kg/m2
IG2: −1.0 kg/m2
WC:
IG1: −9.3 cm
IG2: −5.7 cm
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Table 6. Cont.
Author [56–64] Sample/DiagnosticCriteria
Duration
(Months)
Intervention and
Comparative
Statistical Analysis of
the Body Composition
BW (kg or
z-Score/%)
BF (kg or %
of BW)
FFM
(kg/)
LM
(kg)
BMI
(kg/m2 or % of 95th
Percentile or z-Score)
WC (cm)
Changes in Body
Composition
Mean± sd or
Mean± (SE) or
Mean (CI, 95%)
de Mello et al.,
2011 [56]
n = 30
IG1: 15
IG2: 15
Boys: 67%
Age: 15–19 years old
Population: South
America (Brazil)
Metabolic Syndrome/
Obesity, source of
diagnostic criteria:
IDF/>95th Percentile
12 Physical exercise,
dietary and
psychological
intervention, clinical
therapy
Within groups:
IG1 (aerobic training)
IG2 (aerobic plus
resistance training)
Between groups
YES (kg)
p < 0.05
p < 0.05
p < 0.05
YES (kg and
% of BW)
p < 0.05
p < 0.05
p < 0.05
NO YES
NS
NS
p <
0.05
YES (kg/m2)/NO
p < 0.05
p < 0.05
p < 0.05
YES
p < 0.05
p < 0.05
p < 0.05
BW:
IG1: −7.91 ± 7.48 kg
IG2: −15.45 ± 6.95 kg
BF:
IG1: −5.67 ± 8.05 kg
IG1: −2.87 ± 6.01%IG2: −17.34
± 6.5 kg
IG2: −11.42 ± 6.10%
LM:
IG1: −2.29 ± 4.01 kg
IG2: 2.31 ± 5.22 kg
BMI:
IG1: −2.62 ± 2.35 kg/m2
IG2: −5.54 ± 2.41 kg/m2
WC:
IG1: −5.7 ± 6.37 cm
IG2: −17.06 ± 11.38 cm
Yanovski et al.,
2011 [61]
n = 100
IG1: 53
IG2: 47
Girls: 60%
Age: 6–12 years old
Population: North
America (USA)
Obesity/ Insulin
resistance, source of
diagnostic criteria: ≥
95th Percentile /NE
6 Dietary and physical
exercise intervention,
pharmacology
Within groups:
IG1 (metformin)
IG2 (placebo)
Between groups
YES (kg)
NS
p < 0.05
p < 0.001
YES (kg)
NS
p < 0.05 (1)
NS (2)
p < 0.05
NO NO YES (kg/m2 and
z-score)/NO
p < 0.05
NS
p < 0.05
YES
NS
p < 0.05
p < 0.05
BW:
IG1: 1.47 kg (−0.31, 3.24)
IG2: 4.85 kg (2.84, 6.85)
BF:
IG1: −0.48 kg (−0.8, 1.76) (1)
IG2: −1.88 kg (0.44, 3.31) (1)
IG1: −1.51 kg (−4.56, 1.54) (2)
IG2: 1.81 kg (−1.64, 5.25) (2)
BMI:
IG1: −0.78 kg/m2
(−1.54, −0.01)
IG2: 0.32 kg/m2
(−0.54, 1.18)
IG1: −0.11 (−0.16, −0.05)
(z-score)
IG2: −0.04 (−0.1, 0.02)
(z-score)
WC:
IG1: 1.84 cm (−1, 4.69)
IG2: 4.38 cm (1.23, 7.53)
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Table 6. Cont.
Author [56–64] Sample/DiagnosticCriteria
Duration
(Months)
Intervention and
Comparative
Statistical Analysis of
the Body Composition
BW (kg or
z-Score/%)
BF (kg or %
of BW)
FFM
(kg/)
LM
(kg)
BMI
(kg/m2 or % of 95th
Percentile or z-Score)
WC (cm)
Changes in Body
Composition
Mean± sd or
Mean± (SE) or
Mean (CI, 95%)
Clarson et al.,
2009 [62]
n = 25
IG1: 11
IG2: 14
Boys: 56%
Age: 10–16 years old
Population: North
America (Canada)
Obesity/Insulin
Resistance, source of
diagnostic criteria:
>95th Percentile /NE
6 Physical exercise
intervention, dietary
education,
pharmacology
Within groups:
IG1 (metformin)
IG2 (lifestyle alone)
Between groups
NO NO NO NO YES (kg/m2)
p < 0.05
NS
p < 0.05
YES
NS
NS
NS
BMI:
IG1: −1.8 ± (0.8) kg/m2
IG2: 0.5 ± (0.3) kg/m2
WC:
IG1 and IG2 NE (cm)
Atabek et al., 2008
[63]
n = 120
IG1: 90
IG2: 30
Girls: 50%
Age: 9–17 years old
Population: Europe
(Turkey)
Obesity/Hyperinsulinemia,
source of diagnostic
criteria: >95th
Percentile /NE
6 Dietary and physical
exercise intervention
pharmacology
Within groups:
IG1 (metformin)
IG2 (placebo)
Between groups
YES (kg)
p < 0.001
NS
NE
NO NO NO YES (kg/m2)
p < 0.001
NS
p < 0.01
NO BW:
IG1: −3.4 kg
IG2: 3.6 kg
BMI:
IG1: −2.08 ± 2.32 kg/m2IG2:
0.65 ± 2.5 kg/m2
Love-Osborne et al.,
2008 [64]
n = 64
IG1: 48
IG2: 16
Girls: 71%
Age: 12–19 years old
Population: North
America (USA)
Obesity/Insulin
Resistance, source of
diagnostic criteria:
>95th Percentile /NE
6 Dietary and physical
exercise intervention,
pharmacology
Within groups:
IG1 (metformin)
IG2 (placebo)
Between groups
YES (kg)
NE
NE
NS
NO NO NO YES (kg/m2)
NE
NE
NS
NO BW:
IG1 and IG2: NE (kg)
BMI:
IG1: −0.16 ± 1.89 kg/m2
IG2: 0.63 ± 1.29 kg/m2
Intervention groups (IG); kilograms (kg); centimeters (cm); body weight (BW); body fat (BF); Fat-free mass (FFM); lean mass (LM); Body Mass Index (BMI); medical Subject Heading
(MeSH); metabolic syndrome (MS); study of the analyzed anthropometric parameter (YES); The article does not include its study (NO); not significant (NS); there is a variation of the
anthropometric parameter, but this information is not available in the clinical trial evaluated (NE); percentage (%); waist circumference (WC); (1) BF by air displacement plethysmography
(kg); (2) BF by DEXA (kg); (3) Median (IQR).
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Figure 1. Flow chart of the screening process for the selection of included clinical trials [52–54].
3. Results
3.1. Search Characteristics and Types of Identified Interventions
Of the 1781 clinical trials identified, only 0.51% were included (Figure 1 and Table 5). The most
useful search engine was Web of Science and the most effective search strategy was the fourth (Table 5).
From the most frequently observed characteristics in the randomized clinical trials (Table 6),
we can highlight: completed intervention programs, 55.56% of which had a duration of 6 months
(3 to 18-month range). Six of the studies had a female presence that was slightly larger than the male.
The places of origin were: America (66.67%), Oceania (11.11%) and Europe (22.22%). The age of
participants ranged from 4 to 19 years of age, while the simple size included between 25 to 150 participants
(Median, 58 individuals). The pathology with the most incidence was insulin resistance (66.66%).
All the studies show two intervention groups. The observed intervention modalities were: diet,
physical exercise, psychology, and pharmacology; Multidisciplinary interventions were the most
frequent at 88.89% (Table 6).
Legend of exclusion criteria (Figure 1):
1. I clude a part or a sample without the objective pathology of the systematic revision
2. Dietary and physical exercise interventions or education to changes body composition not defined
3. No comparison or analysis of the anthropometric parameter of interest, before or after intervention
4. Include adult sample (older than 18 years old)
5. Sample not human
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3.2. Variations in Body Composition; Exclusive vs. Multidisciplinary Intervention (Table 6)
In response to the principal objective and research question of this systematic review, the greatest
changes in body composition from the following clinical trials were reported. The Mello MT clinical
trial showed the greatest changes in body composition, in BW (15.45 ± 6.95 kg, which represents a
change with respect to the medium base weight 14.27%), in BF, in kg and in % of BW, of 17.34 ± 6.5 kg
and 11.42 ± 6.10%, respectively in BMI of 5.54 ± 2.41 kg/m2 and in WC of 17.06 ± 11.38 cm. It was a
multidisciplinary intervention of 30 total patients (15 per group) without the use of medication that
combines dietary intervention, physical exercise, and both group and individual psychology from a
medical professional. The intervention that provokes these changes is based on a balanced diet with
energy expenditure of low physical activity, despite the completed physical exercise (which includes
both aerobic and resistance exercises), one hour of group psychology, and monthly medical follow-ups.
This clinical trial is also the only one to present data close to the lean mass (LM). The group which
performed both aerobic and resistance exercises demonstrated greater growth in the body composition
of LM (2.31 ± 5.22 kg) [56].
The Gomez-Diaz clinical trial was the only trial to perform the statistical study of the percentage
changes of BW, obtaining a change of 5.86% in the group treated with metformin (with a range of
2.0–19%). This trial was treated as a multidisciplinary intervention based on the use of a balanced diet,
a normocaloric diet, the inclusion of moderate physical exercise and the use of metformin [60]. None
of the trials perform a study on the percent changes of other parameters.
The Van der Aa. MP clinical trial is the only one which reports information close to the variation
in body composition in FFM. It was a multidisciplinary intervention based on the inclusion of physical
exercise, carried out twice a week with supervision of a physical therapist, and with training courses.
It is the second intervention group to not use metformin [58]. The median range of growth was 4.5 kg
with an interquartile range from 1.3 to 11.6 kg in the group that did not use metformin, versus the
group that did.
In response to the secondary objective of this review, the multidisciplinary interventions are
the ones with the most variation in body composition, especially with the combination of dietary
intervention and physical exercise [56,58,60].
3.3. Anthropometric Parameters and Units of Measurement to Express the Changes in Body Composition
Regarding the final secondary objective of this review, the anthropometric parameters and units
of measurement were BMI in kg/m2 (analyzed by all articles) and BW in kg (8 out of 9 articles).
The percentage of use of the rest of the parameters and units that appear in Table 6, are reflected
in Figure 2.
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In Table 6, the variations of body composition are compiled from each of the 2 intervention groups
for each studied variable. It shows if significant differences are present in the changes within each
intervention group, as well as between them.
With respect to the sole article using exclusive interventions, it studies BW, BF, BMI and WC, but
only reports a statistically significant (p-value < 0.05) change in WC between the intervention groups
(−9.1 ± 4.8 cm in the group with a low insulin response diet versus −6.6 ± 4.6 cm in the group with
conventional diet). It does not report information about differences within groups [57].
Concerning the multidisciplinary intervention trials, 87.5% of them included the study of BW
changes in kg, in z-score and/or relative units. Three of them do not report any information about
the differences within intervention groups (final vs. baseline levels). Regarding the differences in BW
between intervention groups, five present the differences and are statistically significant in four of
the cases.
Regarding BMI, all the papers include the variable for their study in some of the units. All of
them study the parameter in absolute units, but only five report significant differences between the
intervention groups.
The loss in WC is collected in five of the eight works, registering a statistically significant change
between intervention groups in two of them.
As for the rest of the units and parameters, in each case there is only one work that presents
its study.
Figure 3 represents the forest plot of the four works that present data for the calculation of the
variable BMI in kg/m2. All of them are studies where the difference between the two intervention
groups lies on the use or nonuse of metformin. However, it should be noted that they present a high
degree of heterogeneity (I2 = 70.46%).
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4. Discussion
4.1. Changes in Body Composition. Comparison between This Work and Other Reviews and/or Meta-Analyses
The most important variations in the parameters and units used to analyze body composition are
discussed in the following. Comparisons between the main conclusion from this work, as well as from
other reviews, are also included (Table 6).
Until now, reviews and/or meta-analyses that analyze the parameters and units for expressing
body composition in patients with MS or T2DM have not been found. Thus, the comparisons were
made with the reviews and/or meta-analyses of children and adolescents with overweight, obesity,
insulin-resistance or prediabetes.
In this literary search, it has not been possible to find reviews or meta-analyses that present
a clinical trial with a greater variation in body composition that the clinical trials analyzed in this
systematic review [44,65–69].
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Most reviews and/or meta-analyses that have been analyzed do not consider the variation in
body composition that occurs when diet and physical exercise are used as treatment tools in these
patients [7,25,70]. It has been demonstrated that the changes in body composition produce favorable
changes in the metabolic illness risk factors in children, adolescents and adults [71], which is why
further research in this area is recommended.
4.2. Practical Recommendations for the Design of Future Clinical Trials of Patients with Overweight, Obesity,
T2DM and MS (Tables 3 and 4)
Anthropometric parameters and units of measurement express the changes in body composition
through the changes of some parameters (BW, BF, BMI and WC) and increase of other parameters
(FFM and LM). Due to the heterogeneity in the design of clinical trials analyzed here, and considering
the main conclusion from this research, the authors propose the following indications for future trials:
1. Follow the guidelines for the design of randomized trial reports [72] and other randomized
guides [73].
2. The use of the percentage in both the BW as in BF is recommended (in parameters as well as in
the units used), especially when the sample is composed of individuals of different ages and/or
genders [38,41,74–76].
3. The BF is an indicator of the quality of the changes obtained in body composition [38,74,75,77].
4. Set the limit at 5% changes of BF to evaluate the effectiveness of the intervention [38,68,74,78].
5. The changes in body composition (BW, BF and BMI) not only occurs with the assistance of the
patient, but also the consultation as can be seen in Table 4 [74].
6. Based on the lifestyle changes in weight loss programs, the following results were obtained [32]:
(6a) One contact with the patient in ≥26 h, demonstrating small reductions in weight excess in
overweight and obese patients, without evidence of harm. (6b) One contact with the patient in
≥52 h, demonstrating an improved blood pressure and other cardio-metabolic improvements.
7. In the dietary intervention, at the stage of changes in body composition, the type of energy
restriction must be selected depending on the degree of excess weight (Tables 3 and 4). Besides,
the following recommendations must also be considered: (7a) an adaptation in the daily planning
of the energy density and macronutrients if the patient completes the physical exercises regularly,
especially the intake of complex carbohydrates [79]. (7b) be especially cautious regarding
the planning of the carbohydrate intake guidelines for the days where physical exercise is
completed [80].
8. In dietary interventions a period of treatment up to 6 months is recommended, because this is the
time required to reach the maximum average WL and the BF (%) [38,74,81]. Recommendations
for the reduction of body composition are in Table 3 of this review.
9. Tables 3 and 4 summarize the strategies that must be shown by an intervention of physical
exercise in patients looking for changes of body composition (BW, BF, BMI and WC). In addition,
according to the American College of Sports Medicine (ACSM) in clinical trials including physical
exercise, the following aspects should be recorded [82]: (9a) Cardiorespiratory fitness exercise of
resistance: the frequency (days per week), intensity (mild, moderate or vigorous), time (duration),
type, volume (the distance travelled or the expenditure of energy that causes), pattern (one or
more than one session for day) and progression (in volume of exercise adjusted to the duration,
the frequency and/or intensity). (9b) Resistance exercise: frequency (each muscle group should
be trained 2–3 times per week), intensity (mild, moderate or vigorous in function of the maximum
repetitions and on the weight lifted), time (to be determined), the type (depending on the muscle
group involved and the weight lifted); repetitions, session or patterns (rest intervals of 2–3 min
between each set of repetitions; it is recommended ≥48 h between sessions for any muscle group)
and progression (gradual increase of greater resistance, and/or more replicates per set).
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10. In the article by Pieles GE and colleagues (Table 1 and Figure 1), it is shown that progress has
been made in the recommendations for children and adolescents. However, a more accurate
vision should be taken as indicated by ACSM both theoretically and practically to be able to prove
effectiveness [82,83]. For example, in the maintenance and/or reduction of body composition in
patients with overweight, obesity, T2DM and MS, the amount of time they can be seated in front
of the television, must be limited and relative to their ages (Table 4). However, occasionally this
recommendation is not met [84].
11. Mark the objective of the changes in body composition, around a 5, 10 or 15% changes of body
weight or body fat, without necessity to set an ideal BMI [85,86]. One should be cautious when
it comes to not regaining the weight and/or fat [87] and be more tolerant of variations in body
composition [85].
12. Dietician-nutritionists must be involved in the design of the dietary intervention [81,88–90].
13. A healthcare professional must have a role as manager who informs and educates about the most
effective options in the process of decreasing body composition [90,91].
Therefore, it is recommended to follow the recommendations for the design of future clinical
trials of patients with MS. In addition, these recommendations may also be used for patients with
overweight, obesity, pre-diabetes, insulin resistance and T2DM.
4.3. Limitations and Strength of the Systematic Review
The strengths of this systematic review are:
1. The range of search dates of this systematic review, having found 1781 clinical trials
from 2005–2017.
2. The following contributions to the review of this subject: (2a) The MS definitions and diagnostic
criteria (Tables 1 and 2). (2b) A synthesis of guides about the treatment of overweight, obesity,
and T2DM (Tables 3 and 4) together with the development of practical recommendations for the
design of future clinical trials related to MS in children and adolescents. This is due to the lack of
guidelines and consensus on MS in children and adolescents.
3. The trial has been carried out and overseen by professionals versed in dietary intervention and
physical exercise for patients with overweight, obesity, and T2DM [38,39,74,77,90,92,93].
The limitations of this systematic review were previously discussed in the theoretical framework
and in the section on risk methodology of information loss.
5. Conclusions
With the increasing prevalence of MS, the lack of unification in the accepted diagnostic criteria of
MS makes it difficult to determine the prevalence of this syndrome and its use as a diagnostic criterion.
In this systematic review, most of the included clinical trials with children and adolescents
have been diagnosed by at least one MS diagnostic criterion, which implies the lack of use of the
MS definitions.
The relationship between the changes in body composition (changes of some parameters such as
BW, BF, BMI and WC; increase of other parameters such as FFM and LM) and metabolic abnormalities
of the MS, make it advisable to increase the research in this area.
The parameters and units showing the highest changes in body composition were BW (kg) and
BMI (kg/m2).
The evidence is still not clear as to the use of medication in the intervention programs for the
changes of body weight in children and adolescents.
It is proposed to follow the guidelines proposed for patients with overweight, obesity and T2DM
(Tables 3 and 4) and extrapolate these strategies as recommendations to the future clinical trials
designed in patients with MS.
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